Table 4

Subgroup analysis of efficacy and safety of low dose ticagrelor in patients with acute coronary syndrome according to patient characteristics

SubgroupNo of studiesNMACELVEFLVDDMajor bleeding eventsMinor or minimal bleeding eventsNon-bleeding adverse eventsPAgRPRU
Average age (years)
 ≤6042860.33 (0.13, 0.83) I2=0.0%, Z=2.36 (p=0.02)0.87 (0.55, 1.22) I2=81.7%, Z=5.19
(p<0.01)
−0.72 (−1.05, –0.40) I2=0.0%, Z=4.34 (p<0.01)1.00 (0.06, 15.99) I2=0.0%, Z=0.00 (p=1.00)9.35 (0.85, 102.30)*, Z=1.83 (p=0.07)0.36 (0.14, 0.97) I2=17.2%, Z=2.01 (p=0.04)−0.78 (–1.17, –0.40)*, Z=3.98 (P<0.01)−1.92 (−3.00,–0.84)*, Z=3.49 (p<0.01)
 >60 to ≤6589110.41 (0.25, 0.66) I2=0.0%, Z=3.63
(p<0.01)
0.40 (0.23, 0.58) I2=51.3%, Z=4.42
(p<0.01)
−0.25 (–0.42, –0.07) I2=87.6%, Z=2.74
(p<0.01)
1.26 (0.43, 3.68) I2=0.0%, Z=0.42 (p=0.67)1.18 (0.65, 2.13) I2=0.0%, Z=0.54 (p=0.59)0.56 (0.33, 0.94) I2=0.3%, Z=2.18
(p=0.03)
−1.04 (–1.73, –0.34) I2=90.9%, Z=2.92
(P<0.01)
−2.48 (–2.95, –2.00) I2=34.6%, Z=10.19
(P<0.01)
 >6543890.40 (0.14, 1.14) I2=2.2%, Z=1.72 (p=0.07)NRNR0.29 (0.01 to 41.08)*,
Z=0.49 (p=0.62)
2.35 (1.11, 5.02) I2=64.4%, Z=2.22 (p=0.03)0.40 (0.18, 0.89) I2=52.2%, Z=2.25
(p=0.02)
−0.35 (–0.63, –0.07)*, Z=2.46 (p=0.01)NR
Region
 China1315040.38 (0.26, 0.57) I2=0.0%, Z=4.7
(p<0.01)
0.51 (0.35, 0.67) I2=72.0%, Z=6.35
(p<0.01)
−0.36 (–0.52, –0.20) I2=84.0%, Z=4.49
(p<0.01)
1.18 (0.40, 3.49) I2=0.0%, Z=0.29 (p=0.77)1.35 (0.83, 2.19) I2=25.1%, Z=1.21 (p=0.23)0.45 (0.30, 0.69) I2=0.0%, Z=3.70
(p<0.01)
−0.86 (–1.30, –0.42) I2=87.7%, Z=3.81
(p<0.01)
−2.80 (–3.68, –1.92)*, Z=6.21 (p<0.01)
 Korea2105NRNRNR1.10 (0.07, 17.60) I2=0.0%, Z=0.07 (p=0.95)8.89 (1.48, 53.28) I2=0.0%, Z=2.39 (p=0.02)2.23 (0.43, 11.54) I2=0.0%, Z=0.96
(p=0.34)
NR−2.64 (–2.93, –1.99) I2=30.4%, Z=10.29
(p<0.01)
 Greece1201.00 (0.02, 50.40)*, Z=0.00 (p=1.00)NRNR1.00 (0.02, 50.40)*, Z=0.00 (p=1.00)9.35 (0.85, 102.30)*, Z=1.83 (p=0.07)0.11 (0.01, 1.17)*, Z=1.83 (p=0.07)NR−1.92 (–3.00, –0.84)*, Z=3.49 (p<0.01)
Follow-up
 Intervention effect ≤3 months96650.62 (0.25, 1.55) I2=0.0%, Z=1.02 (p=0.31)0.47 (0.24, 0.70) I2=88.0%, Z=4.03
(p<0.01)
−0.40 (–0.62, –0.17) I2=75.2%, Z=3.46
(p<0.01)
0.85 (0.11, 6.67) I2=0.0%, Z=0.16 (p=0.88)1.64 (0.77, 3.50) I2=36.4%, Z=1.27 (p=0.20)0.70 (0.26, 1.91) I2=31.4%, Z=0.70
(p=0.49)
−0.76 (-1.62, 0.09) I2=90.1%, Z=1.76 (p=0.08)−2.46 (–2.85, –2.07) I2=9.2%, Z=12.46
(p<0.01)
 Intervention effect ≥6 months79640.35 (0.22, 0.54) I2=6.3%, Z=4.66
(p<0.01)
0.55 (0.33, 0.77) I2=0.0%, Z=4.93
(p<0.01)
−0.32 (–0.54, –0.10) I2=91.3%, Z=2.89
(p<0.01)
1.26 (0.42, 3.85) I2=0.0%, Z=0.41 (p=0.68)1.64 (0.92, 2.91) I2=47.2%, Z=1.68 (p=0.09)0.45 (0.29, 0.69) I2=0.0%, Z=3.63
(p<0.01)
−0.92 (–1.55, –0.29) I2=89.8%, Z=2.87
(p<0.01)
NR
Ticagrelor dose
 45 mg twice daily72400.32 (0.18, 0.58) I2=0.0%, Z=3.78
(p<0.01)
0.58 (0.13, 1.03)*, Z=2.54 (p=0.01)0.61 (0.16, 1.06) *, Z=2.67 (p=0.01)1.19 (0.40, 3.51) I2=0.0%, Z=0.31 (p=0.76)1.08 (0.47, 2.45) I2=0.0%, Z=0.17 (p=0.86)0.42 (0.15, 1.18) I2=36.8%, Z=1.64
(p=0.10)
−1.66 (–2.54, –0.77) I2=83.7%, Z=3.67
(p<0.01)
−2.83 (–3.45, –2.21) I2=0.0%, Z=8.94
(p<0.01)
 60 mg twice daily2321.00 (0.02, 50.40)*, Z=0.00 (p=1.00)NRNR1.00 (0.02, 50.40)*, Z=0.00 (p=1.00)9.35 (0.85, 102.30)*, Z=1.83 (p=0.07)0.11 (0.01, 1.17)*, Z=1.83 (p=0.07)NR−2.42 (–3.08, –1.76) I2=24.7%, Z=7.16
(p<0.01)
 90 mg once daily84840.45 (0.26, 0.78) I2=0.0%, Z=2.84
(p<0.01)
0.50 (0.33, 0.67) I2=77.5%, Z=5.83
(p<0.01)
−0.50 (–0.66, –0.33) I2=62.9%, Z=5.79
(p<0.01)
1.05 (0.07, 16.78) I2=0.0%, Z=0.03 (p=0.97)1.81 (1.03, 3.19) I2=58.5%, Z=2.05 (p=0.04)0.52 (0.33, 0.80) I2=0.0%, Z=2.95
(p<0.01)
−0.48 (–0.65, –0.30) I2=7.8%, Z=5.37
(p<0.01)
−1.97 (–2.71, –1.23)*, Z=5.19 (p<0.01)
Language
 English41651.00 (0.02, 50.40)*, Z=0.00 (p=1.00)NRNR1.06 (0.14, 10.25) I2=0.0%, Z=0.05 (p=0.96)9.05 (2.16, 37.97) I2=0.0%, Z=3.01
(p<0.01)
0.52 (0.16, 1.66) I2=51.6%, Z=1.11
(p=0.27)
NR−2.46 (–2.85, –2.07) I2=9.2%, Z=12.46
(p<0.01)
 Chinese1214640.38 (0.26, 0.57) I2=0.0%, Z=4.66
(p<0.01)
0.51 (0.35, 0.67) I2=72.0%, Z=6.35
(p<0.01)
−0.36 (–0.52, –0.20) I2=84.0%, Z=4.49
(p<0.01)
1.18 (0.40, 3.49) I2=0.0%, Z=0.29 (p=0.77)1.35 (0.83, 2.19) I2=25.1%, Z=1.20 (p=0.23)0.47 (0.31, 0.73) I2=0.0%, Z=3.44
(p<0.01)
−0.86 (–1.30, –0.42) I2=87.7%, Z=3.81
(p<0.01)
NR
  • * Data was available in only one study.

  • LVDD, left ventricular end diastolic dimension; LVEF, left ventricular ejection fraction; MACE, major adverse cardiac event; NR, not reported; PAgR, platelet aggregation rate; PRU, P2Y12 reaction units.